SYNCOMF · Syncom Formulations (India) Ltd · Biotechnology & Drugs
SYNCOMF · Syncom Formulations (India) Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
26.5% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹126 Cr
Revenue YoY
PAT YoY
+57.8%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
4.2
P/S (TTM)
3.7
Sector P/E
36.3
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SYNCOMF (this stock) | 15.2 | 4.2 | +17.2% | +20.6% | 0 | +0.5% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| SYNCOMF | 2026-09-30 | 15961278 | 3 | WEAK | BULK |
| SYNCOMF | 2026-09-29 | 51188998 | 6 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedThe annual report of Syncom Formulations (India) Limited for FY2025-26 highlights the company's financial performance, including increased net sales and profit after tax compared to the previous year. The report mentions the company's commitment to corporate governance, sustainability, and compliance with regulatory requirements. It also outlines the company's strategic focus on expanding access to high-quality healthcare through operational discipline and scientific progress.
- The company reported increased net sales and profit after tax compared to the previous year.
- Syncom Formulations is committed to corporate governance and compliance with regulatory requirements.
- The company focuses on expanding access to high-quality healthcare through operational discipline and scientific progress.
Key takeaway: Syncom Formulations is committed to expanding access to high-quality healthcare through operational discipline and scientific progress, while navigating challenges such as regulatory price controls and geopolitical conflicts.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company was fined Rs. 2,17,120 by BSE and NSE in February 2024 for non-compliance with Regulation 21(2) regarding failure to form a Risk Management Committee. The company paid the fines to both exchanges by May and June 2024.
The company was fined Rs. 2,000 by BSE and NSE under SEBI's SOP Guidelines as per Regulation 21(2) read with Regulation 3(2) of SEBI (LODR) Regulations, 2015.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has contingent liabilities including income tax demand for A.Y. 2006-07, GST Officer - Indore under Appeal, and GST Officer - Mumbai.
Earlier (1-3 years ago)
The company has several contingent liabilities including appeals with the D C Commercial Tax for F.Y. 2013-14, 2014-15, 2015-16, and GST Officer - Indore and Mumbai, as well as income tax demands for A.Y. 2006-07.
The company has pending appeals with the Deputy Commissioner of Commercial Tax for the fiscal years 2013-14, 2014-15, and 2015-16.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company has disclosed related party transactions involving relatives of Director Mr. Ritesh Kumar Lunkad and other directors, including Mr. Rahul Bankda, Mr. Vijay Bankda, Mrs. Rinki Bankda, and others, with entities such as Vincit Biotech International Private Limited, Synmex Pharma (Partnership), Synmex Pharma Private Limited, and Sante Biotech Private Limited.
Earlier (1-3 years ago)
The company has disclosed related-party transactions involving relatives of directors, including Mr. Vijay Bankda and others, with entities such as Vincit Biotech International Pvt. Ltd., Synmex Pharma Pvt. Ltd., and Sante Biotech Private Limited.
The company has outstanding balances with related parties including Mr. Vijay Bankda, Mr. Kedarmal Bankda, and Mr. Ankit Bankda (CFO) as of 31st March 2024.
Management & Board Governance
2 occurrencesRecent (last 12 months)
Mr. Vijay Shankarlal Bankda, Managing Director and Mr. Kedarmal Shankarlal Bankda, Whole time Director have resigned from the office of Directorship w.e.f., 11th August 2026.
Earlier (1-3 years ago)
Shri Ritesh Kumar Lunkad and Shri Ankit Jain resigned as directors on 14.08.2023. Their resignations were confirmed to have no other material reasons.